Publicaciones en las que colabora con Carlos Panizo Santos (20)

2023

  1. Preclinical models for prediction of immunotherapy outcomes and immune evasion mechanisms in genetically heterogeneous multiple myeloma

    Nature Medicine, Vol. 29, Núm. 3, pp. 632-645

2022

  1. Preneoplastic somatic mutations including MYD88L265P in lymphoplasmacytic lymphoma

    Science Advances, Vol. 8, Núm. 3

2021

  1. Endogenous retroelement activation by epigenetic therapy reverses the warburg effect and elicits mitochondrial-mediated cancer cell death

    Cancer Discovery, Vol. 11, Núm. 5, pp. 1268-1285

  2. Immune biomarkers to predict SARS-CoV-2 vaccine effectiveness in patients with hematological malignancies

    Blood Cancer Journal, Vol. 11, Núm. 12

2019

  1. PD-1/PD-L1 immune checkpoint and p53 loss facilitate tumor progression in activated B-cell diffuse large B-cell lymphomas

    Blood, Vol. 133, Núm. 22, pp. 2401-2412

  2. The mechanism of action of the anti-CD38 monoclonal antibody isatuximab in multiple myeloma

    Clinical Cancer Research, Vol. 25, Núm. 10, pp. 3176-3187

2018

  1. Richter transformation driven by Epstein–Barr virus reactivation during therapy-related immunosuppression in chronic lymphocytic leukaemia

    Journal of Pathology, Vol. 245, Núm. 1, pp. 61-73

2017

  1. A simple flow-cytometry method to evaluate peripheral blood contamination of bone marrow aspirates

    Journal of Immunological Methods, Vol. 442, pp. 54-58

  2. First-line use of rituximab correlates with increased overall survival in late post-transplant lymphoproliferative disorders: retrospective, single-centre study

    European Journal of Haematology, Vol. 98, Núm. 1, pp. 38-43

2013

  1. HLA specificities are related to development and prognosis of diffuse large B-cell lymphoma

    Blood, Vol. 122, Núm. 8, pp. 1448-1454

2011

  1. Neurologic complications of intrathecal liposomal cytarabine administered prophylactically to patients with non-Hodgkin lymphoma

    Journal of Neuro-Oncology, Vol. 103, Núm. 3, pp. 603-609

2010

  1. Enhanced sensitivity of flow cytometry for routine assessment of minimal residual disease

    Haematologica

2009

  1. Splenic marginal zone lymphoma with Evans' syndrome, autoimmunity, and peripheral gamma/delta T cells

    Annals of Hematology

2008

  1. Systemic lupus erythematosus and Franklin's disease: When the somatic mutation mechanism makes a mistake

    Rheumatology

2003

  1. Efficacy and safety of bemiparin compared with enoxaparin in the prevention of venous thromboembolism after total knee arthroplasty: A randomized, double-blind clinical trial

    Journal of Thrombosis and Haemostasis, Vol. 1, Núm. 3, pp. 425-432

  2. Secondary myelodysplastic syndrome after treatment for promyelocytic leukemia: Clinical and genetic features of two cases

    Cancer Genetics and Cytogenetics, Vol. 143, Núm. 2, pp. 178-181

2002

  1. Acquired inhibitor of the intrinsic pathway in a non-haemophilic patient. Control of bleeding by recombinant factor VIIa [11]

    British Journal of Haematology

2001

  1. Caso clínico: Mujer de 21 años con episodios trombóticos de repetición

    Medicine: Programa de Formación Médica Continuada Acreditado, Vol. 8, Núm. 53, pp. 2863-2865

  2. Inhibidores directos de la trombina: Su papel en el tratamiento de la trombosis arterial y venosa

    Medicina Clinica, Vol. 116, Núm. 2, pp. 63-74

2000

  1. Treatment of venous thromboembolism

    Medicina Clinica, Vol. 115, Núm. 6, pp. 224-235